Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Verona Pharma plc is a biotechnology business based in the US. Verona Pharma shares (VRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Verona Pharma employs 25 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $6.75 |
|---|---|
| 52-week range | $3.66 - $9.72 |
| 50-day moving average | $5.53 |
| 200-day moving average | $5.98 |
| Wall St. target price | $20.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.00 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.75 from 2022-01-14
| 1 week (2022-01-12) | -0.30% |
|---|---|
| 1 month (2021-12-17) | 29.81% |
| 3 months (2021-10-19) | 34.46% |
| 6 months (2021-07-19) | 19.05% |
| 1 year (2021-01-19) | -12.34% |
|---|---|
| 2 years (2020-01-17) | 17.39% |
| 3 years (2019-01-18) | 8.00% |
| 5 years (2017-01-15) | N/A |
| Revenue TTM | $40 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -15.77% |
| Return on equity TTM | -31.23% |
| Profit margin | -142.83% |
| Book value | $2.82 |
| Market capitalisation | $405.1 million |
TTM: trailing 12 months
We're not expecting Verona Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Verona Pharma's shares have ranged in value from as little as $3.66 up to $9.722. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verona Pharma's is 0.5819. This would suggest that Verona Pharma's shares are less volatile than average (for this exchange).
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom. .
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.